contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

IDL Diagnostics specializes in oncology and bacteriology. The company has a broad product portfolio, and develops, markets and sells blood and urine sample tests that are used by hospitals and clinics. The tests are intended to provide information for the detection of diseases such as urological cancers and typhoid fever. IDL Diagnostics targets patient groups in different parts of the world. The head office is in Stockholm.

IDL Diagnostics              Article - IDL Diagnostics    [et_pb_section fb_built=”1″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.4″...                             IDL Diagnostics on varmistanut ensimmäisen kaupallisen TPS CLIA -tilauksensa japanilaiselta kumppaniltaan, johtavalta maailmanlaajuiselta japanilaiselta IVD-yritykseltä, Kiinan markkinoille käyttöönotettavaksi.

Alkaen tänään, nimi on IDL Diagnostics AB                   IDL Diagnostics              Article - IDL Diagnostics    [et_pb_section fb_built=”1″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.4″...                             Päivitin otsikon. Uusi ticker on IDLDX

AroCell 3.0 ehdolla vuosikokouksessa:  The board proposes to the annual general meeting (AGM) that AroCell AB changes its name to IDL Diagnostics AB. The main purpose of the name change is to create a stronger connection to the diagnostics industry.             storage.mfn.se              arocells-board-of-directors-proposes-to-the-agm-that-the-parent-company-change-its-name-to-idl-diagnostics-ab.pdf

Suunta on selkeästi oikea. Tämä * Includes costs for goodwill amortization of KSEK 39,578 (39,578) for the period.* ihmetyttää, tuloshan olisi hulppeasti positiivinen mutta tuo jokavuotinen “poisto” kummittelee edelleen luvuissa, mikä hitto se on?

Arocellin Q4 rapsa julkaistu. Naputtelin lukemat nopeasti Exceliin ja näyttää menevän parempaan suuntaan.  Kaiken kaikkiaan ihan hyvä kvartaali: liikevaihdon osalta paras tähän asti, ensimmäinen EBITDA-positiivinen ja kassavirran osalta jo toinen positiivinen neljännes (viimeksi Q2-24).

Taisi mennä väärän firman ketjuun tämä viesti, sillä linkin takaa aukeaa Arise AB:n juttu?

Ja tänään se Kiinan patenttihyväksyntä näköjään sitten tulikin

IDL Diagnostics

IDL Diagnostics, together with its long-term partner concile GmbH, has established a joint venture company. Through this collaboration, IDL Diagnostics' product portfolio will be broadened and...

<div class="mfn-preamble"><p><strong>IDL Diagnostics, together with its long-term partner concile GmbH, has established a joint venture company. Through this collaboration, IDL Diagnostics' product portfolio will be broadened and marketed to a larger market.</strong></p></div><div class="mfn-body"><p>Having signed a letter of intent in May 2025, IDL Diagnostics and the German diagnostics company concile GmbH have created a jointly owned company. The company will drive the global marketing and sales of the companies' products for reader-based rapid tests outside Germany.</p><p>The product portfolio is based on the same type of reader that IDL currently uses for UBC Rapid. This means that we will be able to offer a combination of tests using the same reader to our end users. By expanding the product range with products that are well suited for use together with UBC Rapid, we have a more attractive solution for the end user and enable new revenue streams.</p><p>“The formation of a joint sales company with concile, where we combine our product portfolios and market knowledge, marks an important milestone for IDL. The joint venture will generate revenue streams from new products while facilitating UBC Rapid’s expansion into new markets,” says Anders Hultman, CEO of IDL Diagnostics.</p><p>The joint venture will participate at WHX Labs in Dubai from 10–13 February, where representatives from both Sweden and Germany will promote the company’s rapid tests and how these can be used to deliver accurate and fast results.</p><p>Formally, the agreement is entered into between concile GmbH’s parent company, MBC Holding GmbH, and IDL Diagnostics’ subsidiary IDL Biotech AB.</p></div><div class="mfn-footer mfn-contacts mfn-d7431fd42f58"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p>Anders Hultman, CEO<br>Phone: +46 (0) 8 799 67 50<br>E-mail:&nbsp;<a rel="noopener" href="mailto:anders.hultman@arocell.com">anders.hultman@idldiagnostics.com</a></p></div><div class="mfn-footer mfn-about mfn-3400a8a23fe3"><p><strong class="mfn-heading-1">About IDL Diagnostics</strong></p><hr><p>IDL Diagnostics AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. IDL Diagnostics' product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. IDL Diagnostics (IDLDX) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; <a rel="noopener" href="https://arocell.us12.list-manage.com/track/click?u=afc00720b3f14956d7aa211ee&amp;id=b0c0db8833&amp;e=1eac5f4714">www.idldiagnostics.com</a></p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that IDL Diagnostics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-05 14:01 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/209edbc8-21e7-4897-aa41-5b7b1a5652bb/idl-forms-a-joint-venture-with-concile.pdf" class="mfn-generated mfn-primary">IDL forms a joint venture with concile</a></p></div>